Spero Therapeutics (SPRO) Change in Acquisitions & Divestments (2018 - 2022)

Spero Therapeutics has reported Change in Acquisitions & Divestments for 5 years, with the latest figure at $49.9 million in Q2 2022.

• For the quarter ending Q2 2022, Change in Acquisitions & Divestments rose 143.27% year-over-year to $49.9 million; the trailing twelve-month figure through Mar 2023 stood at $49.9 million (down 11.66% YoY), and the FY2022 full-year result was $60.8 million, up 17.9% from the prior year.
• Change in Acquisitions & Divestments for Q2 2022 stood at $49.9 million, up from $10.9 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $50.6 million in Q1 2019, with the low at $2.0 million in Q4 2020.
• Historically, Change in Acquisitions & Divestments has averaged $20.7 million across 5 years, with a median of $18.3 million in 2020.
• Annual changes were most pronounced in 2020 — Change in Acquisitions & Divestments sank 85.61% — and 2021, when it soared 351.2%.
• Spero Therapeutics' Change in Acquisitions & Divestments stood at $35.5 million in 2018, then sank by 76.03% to $8.5 million in 2019, then plunged by 76.47% to $2.0 million in 2020, then jumped by 250.0% to $7.0 million in 2021, then soared by 612.44% to $49.9 million in 2022.
• The last three Change in Acquisitions & Divestments figures came in at $49.9 million (Q2 2022), $10.9 million (Q1 2022), and $7.0 million (Q4 2021), per Business Quant data.